Skip to main content
Top
Published in: Respiratory Research 1/2022

Open Access 01-12-2022 | Computed Tomography | Correspondence

Increased chest CT derived bone and muscle measures capture markers of improved morbidity and mortality in COPD

Authors: Ava C. Wilson, Jessica M. Bon, Stephanie Mason, Alejandro A. Diaz, Sharon M. Lutz, Raul San Jose Estepar, Gregory L. Kinney, John E. Hokanson, Stephen I. Rennard, Richard Casaburi, Surya P. Bhatt, Marguerite R. Irvin, Craig P. Hersh, Mark T. Dransfield, George R. Washko, Elizabeth A. Regan, Merry-Lynn McDonald

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a disease of accelerated aging and is associated with comorbid conditions including osteoporosis and sarcopenia. These extrapulmonary conditions are highly prevalent yet frequently underdiagnosed and overlooked by pulmonologists in COPD treatment and management. There is evidence supporting a role for bone-muscle crosstalk which may compound osteoporosis and sarcopenia risk in COPD. Chest CT is commonly utilized in COPD management, and we evaluated its utility to identify low bone mineral density (BMD) and reduced pectoralis muscle area (PMA) as surrogates for osteoporosis and sarcopenia. We then tested whether BMD and PMA were associated with morbidity and mortality in COPD.

Methods

BMD and PMA were analyzed from chest CT scans of 8468 COPDGene participants with COPD and controls (smoking and non-smoking). Multivariable regression models tested the relationship of BMD and PMA with measures of function (6-min walk distance (6MWD), handgrip strength) and disease severity (percent emphysema and lung function). Multivariable Cox proportional hazards models were used to evaluate the relationship between sex-specific quartiles of BMD and/or PMA derived from non-smoking controls with all-cause mortality.

Results

COPD subjects had significantly lower BMD and PMA compared with controls. Higher BMD and PMA were associated with increased physical function and less disease severity. Participants with the highest BMD and PMA quartiles had a significantly reduced mortality risk (36% and 46%) compared to the lowest quartiles.

Conclusions

These findings highlight the potential for CT-derived BMD and PMA to characterize osteoporosis and sarcopenia using equipment available in the pulmonary setting.
Appendix
Available only for authorised users
Literature
2.
go back to reference Triest FJJ, Franssen FME, Reynaert N, Gaffron S, Spruit MA, Janssen DJA, et al. Disease-specific comorbidity clusters in COPD and accelerated aging. J Clin Med. 2019;8(4):890.CrossRef Triest FJJ, Franssen FME, Reynaert N, Gaffron S, Spruit MA, Janssen DJA, et al. Disease-specific comorbidity clusters in COPD and accelerated aging. J Clin Med. 2019;8(4):890.CrossRef
3.
go back to reference Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef
4.
go back to reference Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S-S126.PubMedCrossRef Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S-S126.PubMedCrossRef
5.
go back to reference Beaudart C, Biver E, Bruyère O, Cooper C, Al-Daghri N, Reginster JY, et al. Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res. 2018;30(5):413–8.PubMedCrossRef Beaudart C, Biver E, Bruyère O, Cooper C, Al-Daghri N, Reginster JY, et al. Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res. 2018;30(5):413–8.PubMedCrossRef
6.
go back to reference Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O’Donnell M, Sullivan R, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.PubMedCrossRef Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O’Donnell M, Sullivan R, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.PubMedCrossRef
7.
8.
go back to reference Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, et al. Sarcopenia: a time for action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–61.PubMedPubMedCentralCrossRef Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, et al. Sarcopenia: a time for action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–61.PubMedPubMedCentralCrossRef
9.
go back to reference Sepúlveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2021;45:998. Sepúlveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2021;45:998.
10.
go back to reference Zhang L, Sun Y. Muscle-bone crosstalk in chronic obstructive pulmonary disease. Front Endocrinol (Lausanne). 2021;12: 724911.CrossRef Zhang L, Sun Y. Muscle-bone crosstalk in chronic obstructive pulmonary disease. Front Endocrinol (Lausanne). 2021;12: 724911.CrossRef
11.
go back to reference Prado CM, Purcell SA, Alish C, Pereira SL, Deutz NE, Heyland DK, et al. Implications of low muscle mass across the continuum of care: a narrative review. Ann Med. 2018;50(8):675–93.PubMedCrossRef Prado CM, Purcell SA, Alish C, Pereira SL, Deutz NE, Heyland DK, et al. Implications of low muscle mass across the continuum of care: a narrative review. Ann Med. 2018;50(8):675–93.PubMedCrossRef
12.
go back to reference Silva DR, Coelho AC, Dumke A, Valentini JD, de Nunes JN, Stefani CL, et al. Osteoporosis prevalence and associated factors in patients with COPD: a cross-sectional study. Respir Care. 2011;56(7):961–8.PubMedCrossRef Silva DR, Coelho AC, Dumke A, Valentini JD, de Nunes JN, Stefani CL, et al. Osteoporosis prevalence and associated factors in patients with COPD: a cross-sectional study. Respir Care. 2011;56(7):961–8.PubMedCrossRef
13.
go back to reference Wakabayashi H, Sakuma K. Comprehensive approach to sarcopenia treatment. Curr Clin Pharmacol. 2014;9(2):171–80.PubMedCrossRef Wakabayashi H, Sakuma K. Comprehensive approach to sarcopenia treatment. Curr Clin Pharmacol. 2014;9(2):171–80.PubMedCrossRef
14.
go back to reference Lim SY, Bolster MB. Current approaches to osteoporosis treatment. Curr Opin Rheumatol. 2015;27(3):216–24.PubMedCrossRef Lim SY, Bolster MB. Current approaches to osteoporosis treatment. Curr Opin Rheumatol. 2015;27(3):216–24.PubMedCrossRef
15.
go back to reference Morley JE. Treatment of sarcopenia: the road to the future. J Cachexia Sarcopenia Muscle. 2018;9(7):1196–9.PubMedCrossRef Morley JE. Treatment of sarcopenia: the road to the future. J Cachexia Sarcopenia Muscle. 2018;9(7):1196–9.PubMedCrossRef
16.
go back to reference Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang CC, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med. 2011;183(7):885–90.PubMedCrossRef Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang CC, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med. 2011;183(7):885–90.PubMedCrossRef
17.
go back to reference Jaramillo JD, Wilson C, Stinson DS, Stinson DJ, Lynch DA, Bowler RP, et al. Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. Ann Am Thorac Soc. 2015;12(5):648–56. Jaramillo JD, Wilson C, Stinson DS, Stinson DJ, Lynch DA, Bowler RP, et al. Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. Ann Am Thorac Soc. 2015;12(5):648–56.
19.
go back to reference Pacifico J, Geerlings MAJ, Reijnierse EM, Phassouliotis C, Lim WK, Maier AB. Prevalence of sarcopenia as a comorbid disease: A systematic review and meta-analysis. Exp Gerontol. 2020;131: 110801.PubMedCrossRef Pacifico J, Geerlings MAJ, Reijnierse EM, Phassouliotis C, Lim WK, Maier AB. Prevalence of sarcopenia as a comorbid disease: A systematic review and meta-analysis. Exp Gerontol. 2020;131: 110801.PubMedCrossRef
20.
go back to reference Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.PubMedPubMedCentralCrossRef Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.PubMedPubMedCentralCrossRef
21.
go back to reference Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for osteoporosis to prevent fractures: us preventive services task force recommendation statement. JAMA. 2018;319(24):2521–31.PubMedCrossRef Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for osteoporosis to prevent fractures: us preventive services task force recommendation statement. JAMA. 2018;319(24):2521–31.PubMedCrossRef
22.
go back to reference McDonald MN, Diaz AA, Rutten E, Lutz SM, Harmouche R, SanJoseEstepar R, et al. Chest computed tomography-derived low fat-free mass index and mortality in COPD. Eur Respir J. 2017;50:6.CrossRef McDonald MN, Diaz AA, Rutten E, Lutz SM, Harmouche R, SanJoseEstepar R, et al. Chest computed tomography-derived low fat-free mass index and mortality in COPD. Eur Respir J. 2017;50:6.CrossRef
23.
go back to reference Romme EA, Murchison JT, Phang KF, Jansen FH, Rutten EP, Wouters EF, et al. Bone attenuation on routine chest CT correlates with bone mineral density on DXA in patients with COPD. J Bone Miner Res. 2012;27(11):2338–43.PubMedCrossRef Romme EA, Murchison JT, Phang KF, Jansen FH, Rutten EP, Wouters EF, et al. Bone attenuation on routine chest CT correlates with bone mineral density on DXA in patients with COPD. J Bone Miner Res. 2012;27(11):2338–43.PubMedCrossRef
24.
go back to reference McDonald ML, Diaz AA, Ross JC, SanJose ER, Zhou L, Regan EA, et al. Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc. 2014;11(3):326–34.PubMedPubMedCentralCrossRef McDonald ML, Diaz AA, Ross JC, SanJose ER, Zhou L, Regan EA, et al. Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc. 2014;11(3):326–34.PubMedPubMedCentralCrossRef
25.
go back to reference Kim YW, Kim JH, Yoon SH, Lee JH, Lee CH, Shin CS, et al. Vertebral bone attenuation on low-dose chest CT: quantitative volumetric analysis for bone fragility assessment. Osteoporos Int. 2017;28(1):329–38.PubMedCrossRef Kim YW, Kim JH, Yoon SH, Lee JH, Lee CH, Shin CS, et al. Vertebral bone attenuation on low-dose chest CT: quantitative volumetric analysis for bone fragility assessment. Osteoporos Int. 2017;28(1):329–38.PubMedCrossRef
26.
go back to reference van Dort MJ, Driessen JHM, Geusens P, Romme EAPM, Smeenk FWJM, Wouters EFM, et al. Vertebral bone attenuation in Hounsfield Units and prevalent vertebral fractures are associated with the short-term risk of vertebral fractures in current and ex-smokers with and without COPD: a 3-year chest CT follow-up study. Osteoporos Int. 2019;30(8):1561–71.PubMedPubMedCentralCrossRef van Dort MJ, Driessen JHM, Geusens P, Romme EAPM, Smeenk FWJM, Wouters EFM, et al. Vertebral bone attenuation in Hounsfield Units and prevalent vertebral fractures are associated with the short-term risk of vertebral fractures in current and ex-smokers with and without COPD: a 3-year chest CT follow-up study. Osteoporos Int. 2019;30(8):1561–71.PubMedPubMedCentralCrossRef
27.
go back to reference Diaz AA, Zhou L, Young TP, McDonald ML, Harmouche R, Ross JC, et al. Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. Acad Radiol. 2014;21(10):1255–61.PubMedPubMedCentralCrossRef Diaz AA, Zhou L, Young TP, McDonald ML, Harmouche R, Ross JC, et al. Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. Acad Radiol. 2014;21(10):1255–61.PubMedPubMedCentralCrossRef
28.
go back to reference O’Brien ME, Zou RH, Hyre N, Leader JK, Fuhrman CR, Sciurba FC, et al. CT pectoralis muscle area is associated with DXA lean mass and correlates with emphysema progression in a tobacco-exposed cohort. Thorax. 2021;89:56. O’Brien ME, Zou RH, Hyre N, Leader JK, Fuhrman CR, Sciurba FC, et al. CT pectoralis muscle area is associated with DXA lean mass and correlates with emphysema progression in a tobacco-exposed cohort. Thorax. 2021;89:56.
29.
go back to reference Vrieze A, de Greef MH, Wijkstra PJ, Wýkstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int. 2007;18(9):1197–202.PubMedCrossRef Vrieze A, de Greef MH, Wijkstra PJ, Wýkstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int. 2007;18(9):1197–202.PubMedCrossRef
30.
go back to reference Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7(1):32–43.PubMedCrossRef Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7(1):32–43.PubMedCrossRef
31.
go back to reference Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.PubMedCrossRef Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.PubMedCrossRef
32.
go back to reference Martinez CH, Diaz AA, Meldrum CA, McDonald MN, Murray S, Kinney GL, et al. Handgrip strength in chronic obstructive pulmonary disease. Associations with Acute Exacerbations and Body Composition. Ann Am Thorac Soc. 2017;14(11):1638–45.PubMedPubMedCentralCrossRef Martinez CH, Diaz AA, Meldrum CA, McDonald MN, Murray S, Kinney GL, et al. Handgrip strength in chronic obstructive pulmonary disease. Associations with Acute Exacerbations and Body Composition. Ann Am Thorac Soc. 2017;14(11):1638–45.PubMedPubMedCentralCrossRef
33.
go back to reference Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, et al. The 6-minute-walk distance test as a chronic obstructive pulmonary disease stratification tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;194(12):1483–93.PubMedPubMedCentralCrossRef Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, et al. The 6-minute-walk distance test as a chronic obstructive pulmonary disease stratification tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;194(12):1483–93.PubMedPubMedCentralCrossRef
34.
go back to reference Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–33.PubMedPubMedCentralCrossRef Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–33.PubMedPubMedCentralCrossRef
35.
go back to reference Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE. 2012;7(5): e37483.PubMedPubMedCentralCrossRef Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE. 2012;7(5): e37483.PubMedPubMedCentralCrossRef
36.
go back to reference Cox DR, Snell EJ. Analysis of Binary Data. 2nd ed. London: Chapman and Hall; 1989. p. 240. Cox DR, Snell EJ. Analysis of Binary Data. 2nd ed. London: Chapman and Hall; 1989. p. 240.
37.
go back to reference Costa D. Patients with chronic obstructive pulmonary disease have a high prevalence of osteopenia and osteoporosis associated with the worst degrees of pulmonary function and prognosis. J Pulm Respir Med. 2018;45:442. Costa D. Patients with chronic obstructive pulmonary disease have a high prevalence of osteopenia and osteoporosis associated with the worst degrees of pulmonary function and prognosis. J Pulm Respir Med. 2018;45:442.
38.
go back to reference Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209–18.PubMedCrossRef Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209–18.PubMedCrossRef
41.
go back to reference Ehrlich PJ, Lanyon LE. Mechanical strain and bone cell function: a review. Osteoporos Int. 2002;13(9):688–700.PubMedCrossRef Ehrlich PJ, Lanyon LE. Mechanical strain and bone cell function: a review. Osteoporos Int. 2002;13(9):688–700.PubMedCrossRef
42.
43.
go back to reference Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015;70(3):213–8.PubMedCrossRef Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015;70(3):213–8.PubMedCrossRef
44.
go back to reference Franssen FM, Broekhuizen R, Janssen PP, Wouters EF, Schols AM. Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training. Med Sci Sports Exerc. 2005;37(1):2–9.PubMedCrossRef Franssen FM, Broekhuizen R, Janssen PP, Wouters EF, Schols AM. Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training. Med Sci Sports Exerc. 2005;37(1):2–9.PubMedCrossRef
45.
go back to reference Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849–57.PubMedCrossRef Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849–57.PubMedCrossRef
46.
go back to reference Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(5):1115–22.PubMedCrossRef Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(5):1115–22.PubMedCrossRef
47.
go back to reference Singer J, Yelin EH, Katz PP, Sanchez G, Iribarren C, Eisner MD, et al. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function. J Cardiopulm Rehabil Prev. 2011;31(2):111–9.PubMedPubMedCentralCrossRef Singer J, Yelin EH, Katz PP, Sanchez G, Iribarren C, Eisner MD, et al. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function. J Cardiopulm Rehabil Prev. 2011;31(2):111–9.PubMedPubMedCentralCrossRef
48.
go back to reference Mason SE, Moreta-Martinez R, Labaki WW, Strand MJ, Regan EA, Bon J, et al. Longitudinal Association Between Muscle Loss and Mortality in Ever Smokers. Chest. 2022;161(4):960–70.PubMedCrossRef Mason SE, Moreta-Martinez R, Labaki WW, Strand MJ, Regan EA, Bon J, et al. Longitudinal Association Between Muscle Loss and Mortality in Ever Smokers. Chest. 2022;161(4):960–70.PubMedCrossRef
49.
go back to reference Guglielmi G, Ponti F, Agostini M, Amadori M, Battista G, Bazzocchi A. The role of DXA in sarcopenia. Aging Clin Exp Res. 2016;28(6):1047–60.PubMedCrossRef Guglielmi G, Ponti F, Agostini M, Amadori M, Battista G, Bazzocchi A. The role of DXA in sarcopenia. Aging Clin Exp Res. 2016;28(6):1047–60.PubMedCrossRef
50.
go back to reference de Lima TR, Silva DAS, de Castro JAC, Christofaro DGD. Handgrip strength and associated sociodemographic and lifestyle factors: A systematic review of the adult population. J Bodyw Mov Ther. 2017;21(2):401–13.PubMedCrossRef de Lima TR, Silva DAS, de Castro JAC, Christofaro DGD. Handgrip strength and associated sociodemographic and lifestyle factors: A systematic review of the adult population. J Bodyw Mov Ther. 2017;21(2):401–13.PubMedCrossRef
Metadata
Title
Increased chest CT derived bone and muscle measures capture markers of improved morbidity and mortality in COPD
Authors
Ava C. Wilson
Jessica M. Bon
Stephanie Mason
Alejandro A. Diaz
Sharon M. Lutz
Raul San Jose Estepar
Gregory L. Kinney
John E. Hokanson
Stephen I. Rennard
Richard Casaburi
Surya P. Bhatt
Marguerite R. Irvin
Craig P. Hersh
Mark T. Dransfield
George R. Washko
Elizabeth A. Regan
Merry-Lynn McDonald
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-02237-w

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine